Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qu Tan Hua Zhuo granules is a Traditional Chinese Medicine (TCM) formulation developed by Liaoning University of TCM for the treatment of cardiovascular diseases. The name reflects its therapeutic principle in TCM: 'Qu Tan' (eliminating phlegm) and 'Hua Zhuo' (resolving turbidity). It is primarily investigated for use in patients with stable angina pectoris and coronary heart disease who exhibit the 'spleen deficiency generating phlegm' or 'phlegm-turbidity' syndrome. In clinical trials, it is often evaluated as part of an integrative medicine regimen, such as in combination with Yi Qi Jian Pi granules, to improve clinical symptoms, reduce angina frequency, and enhance heart function. The formulation typically consists of a mixture of herbal extracts processed into a granular form for oral administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qu Tan Hua Zhuo granules.